- Home
- LGVN vs GDTC Comparison
LGVN vs GDTC Comparison
Compare LGVN & GDTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LGVN
- GDTC
- Stock Information
- Founded
- LGVN 2014
- GDTC 2018
- Country
- LGVN United States
- GDTC Singapore
- Employees
- LGVN N/A
- GDTC 34
- Industry
- LGVN Medicinal Chemicals and Botanical Products
- GDTC Biotechnology: Pharmaceutical Preparations
- Sector
- LGVN Health Care
- GDTC Health Care
- Exchange
- LGVN Nasdaq
- GDTC Nasdaq
- Market Cap
- LGVN 23.4M
- GDTC 21.5M
- IPO Year
- LGVN 2021
- GDTC 2023
- Fundamental
- Price
- LGVN $1.56
- GDTC $1.94
- Analyst Decision
- LGVN Strong Buy
- GDTC Buy
- Analyst Count
- LGVN 3
- GDTC 1
- Target Price
- LGVN $8.67
- GDTC $5.00
- AVG Volume (30 Days)
- LGVN 827.1K
- GDTC 17.8K
- Earning Date
- LGVN 08-13-2025
- GDTC 01-01-0001
- Dividend Yield
- LGVN N/A
- GDTC N/A
- EPS Growth
- LGVN N/A
- GDTC N/A
- EPS
- LGVN N/A
- GDTC N/A
- Revenue
- LGVN $2,225,000.00
- GDTC $368,838.00
- Revenue This Year
- LGVN N/A
- GDTC $5.37
- Revenue Next Year
- LGVN $51.48
- GDTC N/A
- P/E Ratio
- LGVN N/A
- GDTC N/A
- Revenue Growth
- LGVN 127.50
- GDTC N/A
- 52 Week Low
- LGVN $1.14
- GDTC $1.20
- 52 Week High
- LGVN $4.29
- GDTC $4.05
- Technical
- Relative Strength Index (RSI)
- LGVN 58.78
- GDTC 36.11
- Support Level
- LGVN $1.43
- GDTC $1.85
- Resistance Level
- LGVN $1.80
- GDTC $2.26
- Average True Range (ATR)
- LGVN 0.12
- GDTC 0.11
- MACD
- LGVN 0.01
- GDTC -0.03
- Stochastic Oscillator
- LGVN 58.62
- GDTC 25.00
About LGVN Longeveron Inc.
Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.
About GDTC CytoMed Therapeutics Limited
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.